vs

Side-by-side financial comparison of INDEPENDENT BANK CORP (IBCP) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

INDEPENDENT BANK CORP is the larger business by last-quarter revenue ($58.9M vs $35.5M, roughly 1.7× RECURSION PHARMACEUTICALS, INC.). INDEPENDENT BANK CORP runs the higher net margin — 28.6% vs -304.2%, a 332.9% gap on every dollar of revenue. Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 2.1%).

Independent Bank is a bank headquartered in Grand Rapids, Michigan. The bank has 62 branches, all of which are in Michigan.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

IBCP vs RXRX — Head-to-Head

Bigger by revenue
IBCP
IBCP
1.7× larger
IBCP
$58.9M
$35.5M
RXRX
Higher net margin
IBCP
IBCP
332.9% more per $
IBCP
28.6%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
2.1%
IBCP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IBCP
IBCP
RXRX
RXRX
Revenue
$58.9M
$35.5M
Net Profit
$16.9M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
28.6%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
8.2%
39.6%
EPS (diluted)
$0.81
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBCP
IBCP
RXRX
RXRX
Q1 26
$58.9M
Q4 25
$58.3M
$35.5M
Q3 25
$57.3M
$5.2M
Q2 25
$55.9M
$19.2M
Q1 25
$54.1M
$14.7M
Q4 24
$62.0M
$4.5M
Q3 24
$51.4M
$26.1M
Q2 24
$56.5M
$14.4M
Net Profit
IBCP
IBCP
RXRX
RXRX
Q1 26
$16.9M
Q4 25
$18.6M
$-108.1M
Q3 25
$17.5M
$-162.3M
Q2 25
$16.9M
$-171.9M
Q1 25
$15.6M
$-202.5M
Q4 24
$18.5M
$-178.9M
Q3 24
$13.8M
$-95.8M
Q2 24
$18.5M
$-97.5M
Gross Margin
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Operating Margin
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
34.8%
-304.8%
Q3 25
37.0%
-3327.6%
Q2 25
37.0%
-916.8%
Q1 25
35.3%
-1297.9%
Q4 24
36.7%
-4042.4%
Q3 24
33.7%
-377.1%
Q2 24
41.0%
-697.4%
Net Margin
IBCP
IBCP
RXRX
RXRX
Q1 26
28.6%
Q4 25
31.8%
-304.2%
Q3 25
30.5%
-3135.3%
Q2 25
30.2%
-894.2%
Q1 25
28.8%
-1373.3%
Q4 24
29.8%
-3935.5%
Q3 24
26.9%
-367.5%
Q2 24
32.8%
-676.6%
EPS (diluted)
IBCP
IBCP
RXRX
RXRX
Q1 26
$0.81
Q4 25
$0.88
$-0.17
Q3 25
$0.84
$-0.36
Q2 25
$0.81
$-0.41
Q1 25
$0.74
$-0.50
Q4 24
$0.87
$-0.56
Q3 24
$0.65
$-0.34
Q2 24
$0.88
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBCP
IBCP
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$174.9M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$510.6M
$1.1B
Total Assets
$5.6B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBCP
IBCP
RXRX
RXRX
Q1 26
$174.9M
Q4 25
$138.4M
$743.3M
Q3 25
$208.7M
$659.8M
Q2 25
$146.2M
$525.1M
Q1 25
$128.1M
$500.5M
Q4 24
$119.9M
$594.4M
Q3 24
$121.6M
$427.6M
Q2 24
$214.3M
$474.3M
Total Debt
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Stockholders' Equity
IBCP
IBCP
RXRX
RXRX
Q1 26
$510.6M
Q4 25
$503.0M
$1.1B
Q3 25
$490.7M
$1.0B
Q2 25
$469.3M
$919.1M
Q1 25
$467.3M
$933.9M
Q4 24
$454.7M
$1.0B
Q3 24
$452.4M
$524.6M
Q2 24
$430.5M
$584.4M
Total Assets
IBCP
IBCP
RXRX
RXRX
Q1 26
$5.6B
Q4 25
$5.5B
$1.5B
Q3 25
$5.5B
$1.4B
Q2 25
$5.4B
$1.3B
Q1 25
$5.3B
$1.3B
Q4 24
$5.3B
$1.4B
Q3 24
$5.3B
$726.5M
Q2 24
$5.3B
$775.9M
Debt / Equity
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBCP
IBCP
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
$76.7M
$-46.1M
Q3 25
$18.2M
$-117.4M
Q2 25
$19.0M
$-76.4M
Q1 25
$31.7M
$-132.0M
Q4 24
$63.2M
$-115.4M
Q3 24
$17.2M
$-59.2M
Q2 24
$8.7M
$-82.2M
Free Cash Flow
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
$70.2M
$-47.3M
Q3 25
$16.5M
$-117.6M
Q2 25
$16.7M
$-79.6M
Q1 25
$30.6M
$-133.8M
Q4 24
$55.2M
$-116.7M
Q3 24
$15.7M
$-63.8M
Q2 24
$7.0M
$-83.4M
FCF Margin
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
120.3%
-133.1%
Q3 25
28.9%
-2272.5%
Q2 25
29.8%
-413.9%
Q1 25
56.5%
-907.4%
Q4 24
89.1%
-2567.7%
Q3 24
30.6%
-244.6%
Q2 24
12.3%
-578.5%
Capex Intensity
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
11.1%
3.5%
Q3 25
2.9%
4.7%
Q2 25
4.1%
16.4%
Q1 25
2.1%
12.4%
Q4 24
12.8%
28.6%
Q3 24
2.9%
17.5%
Q2 24
3.1%
8.2%
Cash Conversion
IBCP
IBCP
RXRX
RXRX
Q1 26
Q4 25
4.13×
Q3 25
1.04×
Q2 25
1.12×
Q1 25
2.03×
Q4 24
3.42×
Q3 24
1.25×
Q2 24
0.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBCP
IBCP

Net Interest Income$46.9M80%
Noninterest Income$12.0M20%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons